Iron chelators such as deferoxamine mesylate and ferroptosis inhibitor ferrostatin-1 have been found to significantly alleviate the cell toxicity induced by aristolochic acid I. The Nrf2/HO-1/GPX4 antioxidant signaling pathway may be an important intervention target for preventing drug-induced AKI containing AAI. Here, GPX4 is linked to acute kidney injury.